The short answer
Regulatory frameworks treat an amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug, and anything longer as a protein regulated as a biologic. IGF-1 LR3 is 83 residues, placing it firmly on the protein side.
Key facts
- Threshold
- 40 amino acids
- IGF-1 LR3
- 83 residues
- Classification implied
- Protein: biologic territory
- For contrast, semaglutide
- 31 residues: a drug
- Production
- Recombinant, not synthetic
- Consequence
- Different impurity and folding concerns
Why the line falls where it does
Below roughly forty residues a molecule can generally be synthesised chemically and characterised completely, with every atom accounted for. Above it, synthesis becomes progressively impractical as coupling inefficiency compounds, and folding begins to determine function in ways analysis cannot fully capture. The threshold marks where complete characterisation stops being achievable.
Where this compound falls
Eighty-three residues, more than twice the threshold, with three disulfide bonds and a folded tertiary structure. It is produced by recombinant expression rather than solid-phase synthesis. That is not a coincidence; it is what a molecule of that size and complexity requires.
Research material referenced
IGF-1 LR3 1mg, third-party HPLC tested
What that changes about the impurities
Everything. A synthetic peptide accumulates deletion sequences from incomplete couplings, detectable by mass. A recombinant protein has none of those, because ribosomal synthesis does not fail that way. Instead it carries host cell proteins, host DNA and, from bacterial systems, endotoxin, none of which appears in a protein purity figure.
And what it changes about correctness
For a synthetic peptide, the right sequence is effectively the right molecule. For a folded protein with three disulfide bonds, the right sequence can still be the wrong molecule if the cysteines paired incorrectly, and a misfolded isomer has identical mass. Sequence correctness and molecular correctness separate at this size, and only above the threshold does that separation matter.
Why the classification is hypothetical here
IGF-1 LR3 holds no marketing authorisation anywhere, so no regulator has classified it. The point is what would apply if one did. It explains why the compound's documentation should look like a recombinant protein's rather than a peptide's, which is the practical consequence regardless of regulatory status.
The contrast within this catalogue
Semaglutide at 31 residues, tirzepatide and retatrutide at 39: all synthesisable, all fully characterisable, all handled as drugs. IGF-1 LR3 at 83 sits in a different technical world, and the difference shows up in how it is made, what can go wrong, and what a certificate needs to say. WADA class S2 applies to it regardless, at all times.
Quick reference
| ≤40 residues | IGF-1 LR3, 83 residues | |
|---|---|---|
| Typical production | Chemical synthesis | Recombinant expression |
| Characteristic impurity | Deletion sequences | Host protein, DNA, endotoxin |
| Folding a concern? | Rarely | Yes, three disulfides |
| Detectable by mass? | Impurities generally yes | Misfolds no |
Frequently asked questions
How long is IGF-1 LR3?
83 residues, more than twice the 40-amino-acid threshold that separates peptide from protein in regulatory frameworks.
Why does that matter practically?
It determines production route, impurity profile, and whether folding can go wrong independently of sequence.
Has a regulator classified it?
No. It holds no marketing authorisation anywhere. The point is what would apply, and what its documentation should therefore look like.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedMilner SJ et al., Mutations in the B-domain of IGF-I influence oxidative folding. Biochem J 1995 (PMID 8948444)pubmed.ncbi.nlm.nih.gov
- PubMedJaradat DMM, Thirteen decades of peptide synthesis. Amino Acids 2018 (PMID 29185032)pubmed.ncbi.nlm.nih.gov
- RefUniProt · IGF-1 (P05019)uniprot.org
- RefWADA Prohibited Listwada-ama.org
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More IGF-1 LR3 articles
- What Is IGF-1 LR3? Why It Is a Protein, Not a PeptideAn 83-residue engineered IGF-1 analogue built to evade binding proteins. Why it is a protein rather than a peptide, and what that changes.
- IGF Binding Proteins and the Free FractionMost circulating IGF-1 is sequestered in a ternary complex with IGFBP-3 and the acid-labile subunit. That system is what LR3 was designed to evade.
- IGF-1 LR3 Structure: Three Disulfides and Why They Matter83 residues folded by three disulfide bonds. Milner 1995 showed B-domain mutations affect oxidative folding - and position 3 is in the B-domain.
- Recombinant Versus Synthetic: Two Different Quality ProblemsA recombinant protein has host cell proteins, DNA and endotoxin as impurities. A synthetic peptide has deletion sequences. The certificates should differ.
- IGF-1 LR3 Against the Native Hormone70 residues against 83, and a completely different relationship with binding proteins. Why one is an approved medicine and the other is not.